Meanwhile, A4galt has been reported to be up-regulated in clinical trials of primary aldosteronism (Chenlong et al., 2017), the most common form of endocrine hypertension which has been characterized by excessive and autonomous aldosterone secretion causing increased sodium retention, potassium excretion, hypervolemia, suppressed renin activity and HPN (Rossi, 2011). Here, A4GALT is linked to primary aldosteronism.